PCN99 Cost-Effectiveness Evaluation of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in Kazakhstan

Simple item page
dc.contributor.authorKostyuk, A.
dc.contributor.authorNurgozhin, T.
dc.contributor.authorMazhitov, T.
dc.contributor.authorAlmadiyeva, A.
dc.creatorA., Kostyuk
dc.date.accessioned2017-12-14T04:54:01Z
dc.date.available2017-12-14T04:54:01Z
dc.date.issued2014-05-01
dc.identifierDOI:10.1016/j.jval.2014.03.494
dc.identifier.citationA. Kostyuk, T. Nurgozhin, T. Mazhitov, A. Almadiyeva, PCN99 - Cost-Effectiveness Evaluation of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in Kazakhstan, In Value in Health, Volume 17, Issue 3, 2014, Page A85
dc.identifier.issn10983015
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1098301514005452
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/2888
dc.relation.ispartofValue in Health
dc.rights.licenseCopyright © 2014 Published by Elsevier Inc.
dc.titlePCN99 Cost-Effectiveness Evaluation of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in Kazakhstan
dc.typeArticle
dcterms.publisherValue in Health
elsevier.aggregationtypeJournal
elsevier.coverdate2014-05-01
elsevier.coverdisplaydateMay 2014
elsevier.identifier.doi10.1016/j.jval.2014.03.494
elsevier.identifier.eid1-s2.0-S1098301514005452
elsevier.identifier.piiS1098-3015(14)00545-2
elsevier.issue.identifier3
elsevier.issue.nameISPOR 19th Annual International Meeting Research Abstracts
elsevier.openaccess1
elsevier.openaccessarticletrue
elsevier.openaccessuserlicensehttp://www.elsevier.com/open-access/userlicense/1.0/
elsevier.openarchivearticletrue
elsevier.startingpageA85
elsevier.volume17

Files

Collections

Center for Life Sciences